Preclinical data has demonstrated that epcoritamab is associated with significant in vitro cytotoxic activity against CLL cells derived from patients with treatment-naïve CLL or pretreated with a BTK inhibitor. Here, BTK is linked to B-cell chronic lymphocytic leukemia.